Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06673017
PHASE1

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Sponsor: PanTher Therapeutics

View on ClinicalTrials.gov

Summary

This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

Official title: A Phase Ib Dose Escalation/Dose Expansion Study of PTM-101 as an Adjunct to Neoadjuvant Therapy for Treatment Naïve, Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

26

Start Date

2025-04-14

Completion Date

2028-06

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

DRUG

PTM-101

PTM-101, an absorbable drug product containing paclitaxel

Locations (6)

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Northwell Health Zuckerberg Cancer Center

Lake Success, New York, United States

University of Texas Southwestern Medical Center

Dallas, Texas, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Virginia Mason Medical Center

Seattle, Washington, United States